Pharmamel, a pioneering biotech spin-off from the University of Granada, has successfully raised €2,300,000 in funding to accelerate the development of its groundbreaking intravenous melatonin injectable aimed at treating sepsis, the leading cause of hospital fatalities worldwide. With a strong commitment to addressing critical health challenges, Pharmamel operates under a technology license from both the Andalusian Health Service and the University of Granada. The company's innovative approach incorporates two completed Phase II clinical trials that have effectively demonstrated the safety and efficacy of their drug candidate. This funding round will enable Pharmamel to advance towards pivotal Phase III trials, further validating the therapeutic potential of melatonin in combating sepsis. By enhancing its research and development efforts, Pharmamel is positioned to bring a much-needed solution to healthcare providers and patients grappling with the complexities of this life-threatening condition. Additionally, these funds will support the expansion of Pharmamel’s R&D team and accelerate collaborations with other research institutions, ensuring a comprehensive approach to the advancement of its product. As the medical community seeks new treatment avenues amidst rising sepsis rates, Pharmamel stands at the forefront of innovation with a promising drug candidate that could transform patient outcomes and save lives on a global scale. This encouraging funding announcement marks a significant milestone in the company’s trajectory, reflecting the potential impact of its research and the commitment of its investors to support breakthrough therapies in the biotech landscape.
Pharmamel Secures $2.3 Million Investment to Advance Breakthrough Sepsis Treatment
Recently funded · $2.3MBiotechnology
Get the full Pharmamel company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
